← Back to All US Stocks

Baird Medical Investment Holdings Ltd (BDMDW) Stock Fundamental Analysis & AI Rating 2026

BDMDW Nasdaq Surgical & Medical Instruments & Apparatus E9 CIK: 0001982444
Updated This Month • Analysis: Mar 20, 2026 • SEC Data: 2026-03-20
Combined AI Rating
SELL
84% Confidence
NEUTRAL
STRONG SELL
95% Conf
HOLD
74% Conf

📊 BDMDW Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence
Baird Medical Investment Holdings Ltd (BDMDW) receives a SELL rating with 84% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete BDMDW stock analysis for 2026.

Is Baird Medical Investment Holdings Ltd (BDMDW) a Good Investment?

Claude

Baird Medical Investment Holdings Ltd presents an uninvestable profile due to complete absence of financial data in SEC EDGAR filings. The company shows virtually no operational metrics, no revenue reporting, and no accounting data across income statement, balance sheet, or cash flow statements. Without fundamental financial information, no meaningful analysis of profitability, growth quality, or financial health is possible.

ChatGPT

Baird Medical shows strong underlying profitability, with 2024 revenue up about 18% year over year, gross margin above 88%, and operating income growing faster than sales. However, growth quality is weakened by poor cash conversion, negative operating cash flow, and a large buildup in receivables and prepayments, which makes the otherwise strong earnings profile less durable until working capital normalizes.

Why Buy Baird Medical Investment Holdings Ltd Stock? BDMDW Key Strengths

Claude
  • -No strengths identified
ChatGPT
  • + High-margin business model with 2024 gross profit of about $32.7 million on $37.0 million of revenue
  • + Profitable growth, with operating income rising to about $15.3 million and net income to about $12.6 million in 2024
  • + Equity base remains positive and current assets exceed current liabilities, supporting near-term balance sheet flexibility

BDMDW Stock Risks: Baird Medical Investment Holdings Ltd Investment Risks

Claude
  • ! No revenue or profitability data available
  • ! No balance sheet information or asset base disclosed
  • ! No cash flow metrics to assess operational viability
  • ! Likely pre-revenue or shell company status
  • ! Complete absence of financial transparency
  • ! No insider activity or management conviction signals
ChatGPT
  • ! Operating cash flow was negative in 2024 despite solid net income, indicating weak earnings-to-cash conversion
  • ! Accounts receivable rose to about $46.6 million, materially above annual revenue run-rate, increasing collection and credit-risk exposure
  • ! Customer concentration increased, with four customers representing more than 10% each of 2024 revenue, while liabilities and bank borrowings also climbed sharply

Key Metrics to Watch

Claude
  • * Revenue and gross profit once operations commence
  • * Operating cash flow generation capability
  • * Capital structure and debt levels
ChatGPT
  • * Accounts receivable growth and days sales outstanding versus revenue growth
  • * Operating cash flow and free cash flow recovery relative to reported net income

Baird Medical Investment Holdings Ltd (BDMDW) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BDMDW Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BDMDW vs Healthcare Sector: How Baird Medical Investment Holdings Ltd Compares

How Baird Medical Investment Holdings Ltd compares to Healthcare sector averages

Net Margin
BDMDW 0.0%
vs
Sector Avg 12.0%
BDMDW Sector
ROE
BDMDW 0.0%
vs
Sector Avg 15.0%
BDMDW Sector
Current Ratio
BDMDW 0.0x
vs
Sector Avg 2.0x
BDMDW Sector
Debt/Equity
BDMDW 0.0x
vs
Sector Avg 0.6x
BDMDW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Baird Medical Investment Holdings Ltd Stock Overvalued? BDMDW Valuation Analysis 2026

Based on fundamental analysis, Baird Medical Investment Holdings Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Baird Medical Investment Holdings Ltd Balance Sheet: BDMDW Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BDMDW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BDMDW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Baird Medical Investment Holdings Ltd (CIK: 0001982444)

Frequently Asked Questions about BDMDW

What is the AI rating for BDMDW?

Baird Medical Investment Holdings Ltd (BDMDW) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are BDMDW's key strengths?

Claude: . ChatGPT: High-margin business model with 2024 gross profit of about $32.7 million on $37.0 million of revenue. Profitable growth, with operating income rising to about $15.3 million and net income to about $12.6 million in 2024.

What are the risks of investing in BDMDW?

Claude: No revenue or profitability data available. No balance sheet information or asset base disclosed. ChatGPT: Operating cash flow was negative in 2024 despite solid net income, indicating weak earnings-to-cash conversion. Accounts receivable rose to about $46.6 million, materially above annual revenue run-rate, increasing collection and credit-risk exposure.

What is BDMDW's revenue and growth?

Baird Medical Investment Holdings Ltd reported revenue of N/A.

Does BDMDW pay dividends?

Baird Medical Investment Holdings Ltd does not currently pay dividends.

Where can I find BDMDW SEC filings?

Official SEC filings for Baird Medical Investment Holdings Ltd (CIK: 0001982444) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BDMDW's EPS?

Baird Medical Investment Holdings Ltd has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is BDMDW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Baird Medical Investment Holdings Ltd has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is BDMDW stock overvalued or undervalued?

Valuation metrics for BDMDW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy BDMDW stock in 2026?

Our dual AI analysis gives Baird Medical Investment Holdings Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is BDMDW's free cash flow?

Baird Medical Investment Holdings Ltd's operating cash flow is N/A, with capital expenditures of N/A.

How does BDMDW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2026-03-20 | Powered by Claude AI